



Heart Disease Biotech Stock Catalyst Watchlist

Last updated 4/26/23

Summary:

- Many exciting heart disease catalysts are coming throughout the year
- Already a Pro member? Check out the full list of [Big Movers!](#)
- If not a Pro member...Sign up [here](#) to see all catalyst data!

Table 1. Heart Disease Catalysts & Assets

Ticker	Asset	Indication	Stage	Next Catalyst Event	Catalyst date
LXRX	Sotagliflozin (SGLT1/SGLT2)	HF (Heart Failure)	PDUFA	Approval decision	May 2023 (Est)
BMY	Camzyos®(mavacamten)	Class II-III obstructive hypertrophic cardiomyopathy	PDUFA	Approval decision	June 16,2023
ESPR	Nexletol (bempedoic acid)	HeFH (heterozygous familial hypercholesterolemia) and ASCVD (atherosclerotic cardiovascular disease)	BLA	Submission	H1 2023
BBIO	Acoramidis (AG10)	ATTR-CM	Phase 3	Data readout	Mid 2023
CYTK	Aficamten (CK-274) (cardiac myosin inhibitor)	HCM (Hypertrophic Cardiomyopathies)	Phase 3	Data readout	Q4 2023
AZN	Farxiga	Myocardial infarction	Phase 3	Data readout	H2 2023
CYTK	CK-3828136(CK-136)(cardiac troponin activator)	Heart Failure	Phase 1	Data readout	H2 2023
APLT	AT-001	Diabetic Cardiomyopathy	Phase 3	Data readout	YE 2023/Early 2024
DMAC	DM199 (KLK1 protein)	AIS (Acute Ischemic Stroke)	Phase 2/3	Interim analysis	2023
IONS	Eplontersen (AKCEA-TTR-LRx)	ATTR cardiomyopathy (ATTR-CM)	Phase 3	Data readout	Pro members see all dates
HALO	Selatogrel (P2Y12 receptor antagonist)	AMI (Acute Myocardial Infarction)	Phase 3	Data Readout	Pro members see all dates
CYTK	Omecamtiv Mecarbil (cardiac myosin activator)	HFrEF (Heart Failure with Reduced Ejection Fraction)	NDA	Update	Pro members see all dates
MESO	REVASCOR® (Rexlemestrocel)	CHF (Chronic Heart Failure)	Phase 3	Initiation	Pro members see all dates
CRDL	CardiolRx™	Myocarditis	Phase 2	Data readout	Pro members see all dates
LNTH	Flurpiridaz F 18	Coronary Artery Disease (Detection)	Phase 3	Update	Pro members see all dates